Lantern Pharma Inc. (LTRN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Lantern Pharma Inc. (LTRN) closed at USD 0.67 on 2026-10-14, a change of -83.1 % over the past year, with a market capitalization of USD 9.96M.

Lantern Pharma Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Lantern Pharma Inc. key figures

Previous close

USD 0.67 (2026-10-14)

1-year change

-83.1 %

Market cap

USD 9.96M

Enterprise value

USD 1.2M

P/E ratio (trailing)

-0.43

P/E ratio (forward)

-0.33

EPS (trailing)

-1.55

EPS (forward)

-2.02

PEG ratio

n/a

Price to book

-2.65

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.81

Employees

16

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Lantern Pharma Inc.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Lantern Pharma Inc. and compare it with other stocks.